policy would have taken effect. This could be related to the year on year increase in the percentage of women being sexually active before the age of 16 years: 29.2% according to the latest Natsal survey (Mercer et al, 2013). It seems to us feasible that failing to treat several thousand women with CIN3, along with similar numbers with CIN2 (about a third of which progress to CIN3), may have contributed to the increase in invasive cancers seen in women aged 25–29 years.

Castanon et al (2013a) cite an article of ours (Herbert et al, 2008) that provided preliminary results of a 9-year audit of 133 cervical cancers that was published in 2010 along with concurrent cases of CIN2 + diagnosed at Guy’s and St Thomas’ (Herbert et al, 2010). In that audit we defined screen-detected cancers as those diagnosed in asymptomatic women investigated for abnormal cytology and found that 15 (83.3%) of 18 cancers in women aged 20–29 years were screen-detected IA or IB1 cancers. The treatment of IA cancer is not the same as that of CIN3 as suggested by Castanon et al (2013a), and the effect of a ‘cancer diagnosis’ on a woman as young as 25–29 years may be devastating. During the period of our audit, only 3 of 41 IA cancers had a single large loop excision of the transformation zone (LLETZ), compared with 85 of 100 cases of CIN3 (Table 1). The most frequent treatment of IA cancer was LLETZ followed by knife cone biopsy, because many of these cancers arise in widespread CIN3 that may be difficult to excise completely on a LLETZ; 5 had trachelectomy and 15 had hysterectomies. Most women with CIN3 had a single LLETZ, those who had further treatment tended to be slightly older. LLETZ is less likely to cause premature rupture of membranes than repeated or larger excisional biopsies (Castanon et al, 2013b).

Disabling screening for women aged 20–24 years, whatever their clinical history of sexual activity, is an experiment that is unfortunately taking place during a period of time when there are birth cohorts at increased risk and screening coverage is falling in younger women.1 In our opinion, the view that screening women under age 25 years causes ‘more harm than good’ is letting down a generation of women who are above the ages of those who will benefit from vaccination in the future.

REFERENCES
Castanon A, Leung VMW, Landy R, Lim AW, Sasieni P (2013a) Characteristics and screening history of women diagnosed with cervical cancer aged 20–29 years. Br J Cancer 109: 35–41.

Castanon A, Brocklehurst P, Evans H, Peebles D, Singh N, Walker P, Patrick J, Sasieni P. PaCT Study Group (2013b) Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. Br Med J 343: e5174.

Herbert A, Holdsworth G, Kubba AA (2008) Cervical screening: why young women should be encouraged to be screened. J Fam Plann Reprod Care 34: 21–25.

Herbert A, Anshu, Cullora, Gupta S, Holdsworth G, Kubba A, McLean E, Sim J, Raju SK (2010) Invasive cancer audit: why cancers developed in a high-risk population with an organised screening programme. BJOG 117: 736–745.

Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, Mcdowell W, Lewis R, Field N, Datta J, Copas AJ, Phelps A, Wellings K, Johnson AM (2013) Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 382: 1781–1794.

Office for National Statistics. Available from http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations-england-series-mbl1/index.html (accessed 20 August 2014).

Sir,

Dr Herbert et al (2014, this issue) suggest that women in England born between 1985 and 1995 have been ‘let down’ by the National Health Service. It is true that most would neither have been vaccinated against HPV types 16 and 18 nor have been invited to screening between age 20–24. However, we reject the notion that they have been let down. We have estimated elsewhere (Landy et al, 2014) that the change in policy (inviting women for screening from age 25 instead of from age 20) will have resulted in about 2800 fewer women per 100,000 being treated for cervical intraepithelial neoplasia and have led to at most 23 extra cancers, of which between 3 and 9 would have been stage IB or worse. We have seen no new data that would lead us to change these estimates. By way of contrast, we have also estimated that introducing a more sensitive screening test (such as primary HPV testing) in women aged 25–64 could prevent 168 cancers per 100,000 women (even without changing the coverage) (Castanon et al, 2013).

We agree with Dr Herbert et al that 1A1 cancers may sometimes be treated with a knife cone under a general anaesthetic rather than by loop excision under a local anaesthetic, but we suggest that the audit data they present are out of date and not representative of England today. In our audit, 92% (887 of 965) women aged 20–29 with stage IA cancer diagnosed since April 2007 had a cone excision. It is difficult to believe that it is desirable to treat over 100 women with high-grade cervical intraepithelial neoplasia by a cone excision in order to prevent one case of IA cervical cancer that will also be treated by cone excision (albeit possibly a more invasive one).

The decision to only invite women for cervical screening from age 25 is clearly emotive, but it is not helpful to refer to it as an unfortunate experiment. It was based on an independent committee’s unanimous view that screening women aged 20–24 was likely to cause more harm than benefit. It was certainly not intended to be an experiment, nor does it constitute a particularly good natural experiment. Taking into account all subsequent evidence, we remain convinced that the combined effect of policies announced in October 2003 (switching from conventional cytology to liquid-based cytology; first invitation at age 25; 3-yearly screening for women aged 25–49 instead of 5-yearly, as was the practice in some parts of England; and 5-yearly screening from age 50 to 64) was for the overall good of women in England.

REFERENCES
Castanon A, Landy R, Sasieni P (2013) How much could primary human papillomavirus testing reduce cervical cancer incidence and morbidity? J Med Screen 20(2): 99–103.

Herbert A, Holdsworth G, Kubba AA (2014) Comment on ‘Characteristics and screening history of women diagnosed with cervical cancer aged 20–29’. Br J Cancer 111(10): 2043.

Landy R, Birke H, Castanon A, Sasieni P (2014) Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer 110(7): 1841–1846.

Response to comment on ‘Characteristics and screening history of women diagnosed with cervical cancer aged 20–29’

A Castanon*,1, R Landy1, A W Lim1 and P Sasieni1

1Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

*Correspondence: Dr A Castanon; E-mail: a.castanon@qmul.ac.uk
Published online 28 August 2014
© 2014 Cancer Research UK. All rights reserved 0007 – 0920/14